We found that the combination of cetuximab (anti-EGFR mAb) and trastuzumab (anti-HER2 mAb) is efficient against pancreatic cancer (10–12), a disease with unmet medical needs and poor prognosis (15). The gene discussed is EGFR; the disease is pancreatic neoplasm.